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Sir,
We thank Dr Rezaei Kalantari for his interest in our study.
Dr Rezaei Kalantari describes two patients with side effects
requiring dose reduction of sunitinib, but who appeared to have
developed an improved tolerance to sunitinib after re-escalation of
the dose. As the dosing schedule of sunitinib is fixed as
50mg day1 for 4 weeks on and 2 weeks off regardless of the
differences in pharmacokinetic behaviour between individuals, it
may be expected that some patients tolerate higher doses, whereas
others need dose reduction (Van der Veldt et al, 2008). We agree
that dose escalation needs to be considered in patients without side
effects when aiming for a tumour response. The probability of a
greater response and survival increases with higher drug exposure
in metastatic renal cell cancer, although the survival of patients
treated with lower sunitinib doses on a continuous daily base
overlaps with that of patients treated with standard dosing
(Escudier et al, 2009). The two cases mentioned by Dr Rezaei
Kalantari are indeed interesting, because dose reduction was
initially required because of a series of side effects. Unfortunately,
it is not mentioned whether baseline disease symptoms in these
patients aggravated the adverse events. Patients recovered in cycles
3–4, suggesting that adverse events not only disappeared by
reducing the dose but also because of a clinical response to
sunitinib. It is also not clear whether the patients were taking co-
medication that could have interfered with pharmacokinetics of
sunitinib. Sunitinib is metabolised primarily by the cytochrome
P450 (CYP) 3A4 isozyme to the active metabolite SU012662, which
is further metabolised by CYP3A4 (Adams and Leggas, 2007). The
parent compound and active metabolite reach similar plasma
concentrations and have similar biochemical activity and potency.
Besides the well-known inhibitors and inducers of CYP3A4, many
other drugs may affect the drug metabolism by CYP3A4. For
example, statins have been shown to increase CYP3A expression in
vitro (Willrich et al, 2009). Thus far, no evidence of autoinduction
of sunitinib or SU012662 metabolism has been observed with
prolonged dosing. As mentioned earlier, measurements of plasma
levels of sunitinib and its active metabolite may be of value to
determine the dose of sunitinib in particular individuals, such as in
obese patients (Desar et al, 2009). For the time being, because
sunitinib plasma levels cannot be determined routinely, it seems
plausible to consider dose re-escalation in fit patients upon signs
of disease progression.
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